Azenta appoints Trey Martin as Multiomics President; Ginger Zhou steps down

Azenta, Inc.

Trey Martin appointed President of Multiomics effective April 6, 2026; reports to CEO John Marotta.
Martin most recently served as CEO of Maravai LifeSciences (MRVI) and previously led IDT under Danaher (DHR).
Ginger Zhou stepped down as President; she will remain as advisor through November 2026 under a consulting agreement with $103,500 initial fee.
Executive officers Lawrence Lin, Ephraim Starr, and Olga Pirogova received amended offer letters clarifying severance and change-in-control terms.
Azenta aims to accelerate Multiomics long-range plan focusing on global synthesis scale, operational excellence, and profitable growth.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.